An appraisal of the value of vitamin B 12 in the prevention of motion sickness

Abstract

Unpublished reports have suggested that hydroxycobalamin (B 12, i.m.) prevents motion sickness. Some biomedical evidence supports this contention in that B 12 influences the metabolism of histidine and choline; dietary precursors to neurotransmitters with established roles in motion sickness. Susceptibility to motion sickness was evaluated after B 12 (1000 μg, i.m.). Subjects initially completed vestibular function and motion sickness susceptibility tests to establish normal vestibular function. The experimental motion stressor was a modified coriolis sickness susceptibility test. Subjects executed standardized head movements at successively higher RPM until a malaise III endpoint was reached. Following two baseline tests with this motion stressor, subjects received a B 12 injection, a second injection two weeks later, and a final motion sickness test three weeks later. No significant differences in susceptibility were noted after B 12. Hematological parameters revealed no B 12 deficiency before injection. The possibility that patients with B 12 deficiencies are more susceptible to motion sickness cannot be ruled out.